Last Updated: September 24, 2026

Hisun Pharm Hangzhou Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for HISUN PHARM HANGZHOU

HISUN PHARM HANGZHOU has twenty-two approved drugs.

Summary for Hisun Pharm Hangzhou

US Patents:	0
Tradenames:	19
Ingredients:	19
NDAs:	22

Drugs and US Patents for Hisun Pharm Hangzhou

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hisun Pharm Hangzhou	OLANZAPINE	olanzapine	TABLET;ORAL	206924-005	Dec 31, 2020		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Hisun Pharm Hangzhou	IRINOTECAN HYDROCHLORIDE	irinotecan hydrochloride	INJECTABLE;INJECTION	090016-001	Jan 28, 2009		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Hisun Pharm Hangzhou	LOSARTAN POTASSIUM	losartan potassium	TABLET;ORAL	204795-003	Apr 4, 2019		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Hisun Pharm Hangzhou	TELMISARTAN	telmisartan	TABLET;ORAL	207843-003	Feb 19, 2019		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Hisun Pharm Hangzhou

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.